Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc.（ACHV）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ACHV · 截至 2025年9月30日
股东结构概览
72
机构持有人数
▲ 4 vs Q2
$48.92M
机构持仓总市值
▼ $10.38M vs Q2
102.66M
总流通股
freeFloat 84.99%
15.54M
13F 申报持股数
▼ 10.70M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ACHV 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
PROPEL BIO MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 3.79M | 10.92% | 10.92% | $11.93B | Nov 12, 2025 | ▼ 2.37M |
VANGUARD GROUP INC in vitro & in vivo diagnostic substances | 2.46M | 7.10% | 7.10% | $7.75B | Nov 7, 2025 | ▲ 311.9K |
SIMPLIFY ASSET MANAGEMENT INC. in vitro & in vivo diagnostic substances | 1.18M | 3.42% | 3.42% | $3.73B | Oct 20, 2025 | — held |
MARSHALL WACE, LLP in vitro & in vivo diagnostic substances | 774.9K | 2.23% | 2.23% | $2.44B | Nov 13, 2025 | NEW |
NANTAHALA CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 648.9K | 1.87% | 1.87% | $2.04B | Nov 14, 2025 | ▼ 250.0K |
GEODE CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 507.0K | 1.46% | 1.46% | $1.60B | Nov 12, 2025 | ▲ 144.8K |
PATHSTONE HOLDINGS, LLC in vitro & in vivo diagnostic substances | 502.0K | 1.45% | 1.45% | $1.58B | Nov 13, 2025 | NEW |
RAYMOND JAMES FINANCIAL INC in vitro & in vivo diagnostic substances | 456.4K | 1.32% | 1.32% | $1.44B | Nov 14, 2025 | ▲ 161.3K |
CLEARLINE CAPITAL LP in vitro & in vivo diagnostic substances | 451.2K | 1.30% | 1.30% | $1.42B | Nov 14, 2025 | ▼ 875.0K |
TWO SIGMA INVESTMENTS, LP in vitro & in vivo diagnostic substances | 439.1K | 1.27% | 1.27% | $1.38B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
22
增持
+2.21M 股13
新建仓
首次建仓10
减持
−11.54M 股0
清仓
完全退出净股数变化（前50家）
9.33M
+2.21M / −11.54M
净新增持仓人
+25
新建 13 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ACHV 内幕交易记录
数据来源：SEC Form 4
4
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Waldman Reid Alexander director | May 29, 2026 | Award | 47,250 | $5.24 | $247.6K | 47.3K | Form 4 ↗ |
Farrow Jeffrey S director | May 29, 2026 | Award | 47,250 | $5.24 | $247.6K | 47.3K | Form 4 ↗ |
Martin Christopher Nathan director | May 11, 2026 | Award | 47,250 | $5.59 | $264.1K | 47.3K | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 11,706,270 | — | — | 11.71M | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 3,601,929 | $4.25 | $15.31M | 3.60M | Form 4 ↗ |
Goldberg Andrew D. CEO and President | Apr 18, 2026 | Award | 1,800,965 | — | — | 1.80M | Form 4 ↗ |
Rubinstein Mark Lawrence Chief Medical Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Oki Mark K Chief Financial Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Xinos Jaime Chief Commercial Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
Donnelly Craig Chief Operations Officer | Jan 28, 2026 | Award | 180,000 | $4.36 | $784.8K | 180.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Achieve Life Sciences, Inc.（ACHV）主要由机构投资者持有，机构持股比例约为 15.1%。公司内部人员持股约 15.01%，散户及公众持股约占剩余的 69.85%。
Achieve Life Sciences, Inc. 最大机构股东为 PROPEL BIO MANAGEMENT, LLC，截至 September 30, 2025 持有约 3.79 million 股，占总流通股的 10.92%。
目前共有 72 家机构持有 ACHV 股票，合计持仓市值约 $48,921,838，数据来源为最新 SEC 13F 申报。
常见问题
ACHV ownershipAchieve Life Sciences, Inc.（ACHV）主要由机构投资者持有，机构持股约 15.1%。最大股东为 PROPEL BIO MANAGEMENT, LLC，持股比例 10.92%。内部人员持股约 15.01%。数据来源 SEC Form 13F，截至 September 30, 2025。